Trametinib s2673

Manufactured by Selleck Chemicals

Sourced in United States

Trametinib (S2673) is a synthetic small molecule that acts as a selective inhibitor of mitogen-activated protein kinase kinase (MEK) enzymes. It is used as a laboratory reagent for research purposes.

Automatically generated - may contain errors

Lab products found in correlation

Pd0325901 s1036, by Selleck Chemicals (1 mentions) Dabrafenib, by GlaxoSmithKline (1 mentions) Penicillin, by Thermo Fisher Scientific (1 mentions) Pen strep, by American Type Culture Collection (1 mentions) Streptomycin pen strep, by Thermo Fisher Scientific (1 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (1 mentions) Geneticin g418, by Thermo Fisher Scientific (1 mentions) Bgj398 s2183, by Selleck Chemicals (1 mentions) Pierce protein a g magnetic beads, by Thermo Fisher Scientific (1 mentions) Lipofectamine 2000, by Thermo Fisher Scientific (1 mentions) Pngase f, by New England Biolabs (1 mentions)

3 protocols using trametinib s2673

Drosophila Genetics for Tumor Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Crosses were set up with esg-GAL4, tub-GAL80^TS, UAS-GFP and UAS-yki^3SA or UAS-dERK^SEM; UAS-yki^3SA at 18°C to inactivate GAL4. 4-day-old adult progenies were placed at 29°C to induce the transge nes. For the in vivo RNAi screening of ligands in yki^3SA-tumor guts, different RNAi lines were crossed to esg-GAL4, tub-GAL80^TS, UAS-GFP/CyO; UAS-yki^3SA/TM6B at 18 °C . Virgin progenies were maintained at 18 °C for at least 8 d ays and then switched to 29 °C to induce transgenes. Lipid and sugar levels, cl imbing speed, and muscle morphology, gut morphology, and bloating phenotypes were all measured after switching to 29 °C for 8 days. For drug treatment, flies were transferred onto food containing inhibitors at day 0 (simultaneously with tumor induction) or day 4 (after tumor formation). MEK/ERK inhibitors PD0325901 (S1036) and Trametinib (S2673) were purchased from Selleckchem.

Song W., Kir S., Hong S., Hu Y., Wang X., Binari R., Tang H.W., Chung V., Banks A.S., Spiegelman B, & Perrimon N. (2019). Tumor-derived ligands trigger tumor growth and host wasting via differential MEK activation. Developmental cell, 48(2), 277-286.e6.

+ Open protocol

+ Expand

Cell Culture and Drug Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

HEK293T cells were kindly provided by Prof. Ron Kooijman (FARC, Vrije Universiteit Brussel) and were cultured in Dulbecco’s Modified Eagles Medium (DMEM) (Life Technologies, 31966-047) supplemented with 10% fetal bovine serum (FBS) (Perbio Science, SV30160.03) and 100 U/ml penicillin 100 μg/ml streptomycin (pen-strep) (Life Technologies, 15140-148). H1666 cells were purchased from the ATCC (CRL-5885) and cultured in F12-based (ATCC: 30-2006) ACL-4 medium supplemented with 10% FBS and pen-strep. Both cell lines were tested periodically for mycoplasma infection, and all tests were negative. Dabrafenib (Tafinlar) was provided by GlaxoSmithKline (UK). Trametinib (S2673) and AZ628 (S2746) were obtained from Selleckchem (USA).

Noeparast A., Giron P., De Brakeleer S., Eggermont C., De Ridder U., Teugels E, & De Grève J. (2018). Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. Oncotarget, 9(22), 16110-16123.

+ Open protocol

+ Expand

FGFR3 Signaling Pathway Antibody Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies were purchased from: FGFR3 (B-9), FGFR3 (P18) from Santa Cruz Biotechnology (Dallas, TX, USA); FGFR3 (OAAB11172) from Aviva Systems Biology (San Diego, CA, USA); phospho-p44/42 MAPK (ERK 1/2; T202/Y204; D13.14.4E), p44/42 MAPK (ERK 1/2, 9102) from Cell Signaling Technology (Danvers, MA, USA); EEA1 (610456) from BD Biosciences (San Jose, CA, USA); Alexa Fluor 488 donkey anti-goat (A11055), Alexa Fluor 594 donkey anti-goat (A11058), Alexa Fluor 488 donkey anti-mouse (A21202) from Invitrogen (Carlsbad, CA, USA); horseradish peroxidase (HRP) anti-mouse, HRP anti-rabbit, and Enhanced Chemiluminence (ECL) reagents were from GE Healthcare (Little Chalfont, UK). Geneticin (G418) was from Gibco (Waltham, MA, USA), and Lipofectamine 2000 was from Invitrogen (Carlsbad, CA, USA). PNGase F was purchased from NEB (P0704S) and Pierce Protein A/G Magnetic Beads (88802) were purchased from Thermo Fisher (Waltham, MA, USA). Inhibitors BGJ398 (S2183) and Trametinib (S2673) were purchased from Selleckchem (Houston, TX, USA).

Nelson K.N., Meyer A.N., Wang C.G, & Donoghue D.J. (2018). Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling. Oncotarget, 9(76), 34306-34319.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!